Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G- sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treat...
The dosage of penicillin V potassium tablets and penicillin V potassium for oral solution should be determined according to the sensitivity of the causative microorganisms and the severity of the infection, and adjusted to the clinical response of the patient. The usual dosage recommendations for adults and children 12 years and over are as follows: Streptococcal infections Mild to moderately severe - of the upper...
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Penicillin V exerts a bactericidal action against penicillin-sensitive microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci. The drug exerts high in vitro activity against staphylococci (except penicillinase-producing strains), streptococci (groups A, C, G, H, L and M) and pneumococci. Other organisms sensitive in vitro to penicillin V are Corynebacterium diphtheriae, Bacillus anthracis, Clostridia, Actinomyces bovis, Streptobacillus moniliformis, Listeria monocytogenes, Leptospira and Neisseria gonorrhoeae. Treponema pallidum is extremely sensitive.
The potassium salt of penicillin V has the distinct advantage over penicillin G in resistance to inactivation by gastric acid. It may be given with meals; however, blood levels are slightly higher when the drug is given on an empty stomach. Average blood levels are two to five times higher than the levels following the same dose of oral penicillin G and also show much less individual variation.
Once absorbed, penicillin V is about 80% bound to serum protein. Tissue levels are highest in the kidneys, with lesser amounts in the liver, skin, and intestines. Small amounts are found in all other body tissues and cerebrospinal fluid. The drug is excreted as rapidly as it is absorbed in individuals with normal kidney function; however, recovery of the drug from the urine indicates that only about 25% of the dose given is absorbed. In neonates, young infants, and individuals with impaired kidney function, excretion is considerably delayed.
Susceptibility Testing
Diffusion Techniques
Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure 2,4 which has been recommended for use with disks to test susceptibility of organisms to penicillin uses the 10 unit (U) penicillin disk. Interpretation involves the correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for penicillin.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 U penicillin disk should be interpreted according to the criteria provided in
Table 1.
Dilution Techniques
Quantitative methods that are used to determine minimum inhibitory concentrations (MICs) provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure 3,4 uses a standardized dilution method (broth or agar) or equivalent with penicillin powder. The MIC values obtained should be interpreted according to the criteria provided in Table 1.
Pathogen | Susceptibility Test Result Interpretive Criteria | |||||
Disk diffusion (Zone diameter in mm) | Minimal Inhibitory Concentration (MIC in mcg/mL) | |||||
S | I | R | S | I | R | |
Staphylococcus spp. | >29 | - | <28 | <0.12 | - | >0.25 |
Streptococcus spp. (beta-hemolytic group) | >24 | - | - | <0.12 | - | - |
Streptococcus pneumoniae (non-meningitis isolates) | <0.06 | 0.12-1 | >2 | |||
A report of “susceptible” (S) indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in the blood. A report of “intermediate” (I) indicates that the result should be considered equivocal, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “resistant” (R) indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Quality Control
Standardized susceptibility test procedures require the use of laboratory control microorganisms 2,3,4. The 10 U penicillin disk and the standard penicillin powder should provide respectively the following zone diameters and MIC values in these quality laboratory test control strains:
Microorganism | Acceptable Quality Control Ranges | |
Disk diffusion (Zone diameter ranges in mm) | Minimal Inhibitory Concentration Range (MIC in mcg/mL) | |
Staphylococcus aureus ATCC 25923 | 26-37 | |
Staphylococcus aureus ATCC 29213 | 0.25-2 | |
Streptococcus pneumonia ATCC 49619 | 24-30 | 0.25-1 |
Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G- sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed.
The following Infections will usually respond to adequate dosage of Penicillin V:
Streptococcal infections (without bacteremia):
Mild-to-moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas.
NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant.
Pneumococcal infections:
Mild to moderately severe infections of the respiratory tract.
Staphylococcal infections - penicillin G sensitive:
Mild infections of the skin and soft tissues.
NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections.
Fusospirochetosis (Vincent's gingivitis and pharyngitis):
Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.
NOTE: Necessary dental care should be accomplished in infections involving the gum tissue.
Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions.
Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen.
NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
A previous hypersensitivity reaction to any penicillin is a contraindication.
SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (anaphylactic) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH PENICILLIN V POTASSIUM, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, PENICILLIN V POTASSIUM SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma.
Prescribing Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilatation, cardiospasm or intestinal hypermotility.
Occasionally patients will not absorb therapeutic amounts of orally administered penicillin.
In streptococcal infections, therapy must be sufficient to eliminate the organism (ten-day minimum): otherwise the sequelae of streptococcal disease may occur. Cultures should be taken following completion of treatment to determine whether streptococci have been eradicated.
Prolonged use of antibiotics may promote the overgrowth of nonsusceptible organisms, including fungi. Should superinfection occur, appropriate measures should be taken.
Oral Solutions contain aspartame. Phenylketonurics: Both the 125 mg and 250 mg Oral Solutions contain phenylalanine 4.5 mg per 5 mL.
Patients should be counseled that antibacterial drugs, including Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution should only be used to treat bacterial infections. They do not treat viral infections (e.g. the common cold).
When Penicillin V Potassium Tablets or Penicilin V Potassium Oral Solution are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may:
(i) Decrease the effectiveness of the immediate treatment, and
(ii) Increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin-VK or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin.
The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sicknesslike reactions, laryngeal edema and anaphylaxis.
Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.
The dosage of penicillin V potassium tablets and penicillin V potassium for oral solution should be determined according to the sensitivity of the causative microorganisms and the severity of the infection, and adjusted to the clinical response of the patient.
The usual dosage recommendations for adults and children 12 years and over are as follows:
Streptococcal infections
Mild to moderately severe - of the upper respiratory tract and including scarlet fever and erysipelas: 125 mg to 250 mg (200,000 to 400,000 units) every 6 to 8 hours for 10 days.
Pneumococcal infections
Mild to moderately severe - of the respiratory tract, including otitis media: 250 mg to 500 mg (400,000 to 800,000 units) every 6 hours until the patient has been afebrile for at least 2 days.
Staphylococcal infections
Mild infections of skin and soft tissue (culture and sensitivity tests should be performed): 250 mg to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.
Fusospirochetosis (Vincent's infection)
of the oropharynx. Mild to moderately severe infections: 250 mg to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.
For the prevention of recurrence following rheumatic fever and/or chorea: 125 mg to 250 mg (200,000 to 400,000 units) twice daily on a continuing basis.
For prophylaxis against bacterial endocarditis 1 in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures or surgical procedures of the upper respiratory tract: 2 grams of penicillin V (1 gram for children under 60 lbs) 1 hour before the procedure, and then 1 gram (500 mg for children under 60 lbs) 6 hours later.
Prepare solution at the time of dispensing by adding the water in two portions to the bottle as follows: Loosen powder by tapping the bottle, add about half the water, and shake well. Add the remaining water and shake well to complete solution. Each teaspoon (5 mL) will contain Penicillin V Potassium equivalent to 125 mg or 250 mg of Penicillin V.
Product | Bottle Size | Amount of water required for reconstitution |
125 mg/5 mL | 100 mL | 65 mL |
200 mL | 127 mL | |
250 mg/5 mL | 100 mL | 65 mL |
200 mL | 127 mL |
Note: Shake the oral solution well before using.
Store the reconstituted solution in a refrigerator. Discard any unused portion after 14 days. Keep the bottle tightly closed.
Penicillin V Potassium Tablets, USP 250 mg (400,000 units) - White, oval, biconvex tablets engraved S20.
NDC 67253-200-10 Bottles of 100
NDC 67253-200-11 Bottles of 1,000
Penicillin V Potassium Tablets, USP 500 mg (800,000 units) -White, oval, biconvex tablets engraved S21.
NDC 67253-201-10 Bottles of 100
NDC 67253-201-50 Bottles of 500
NDC 67253-201-11 Bottles of 1,000
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Keep tightly closed. Protect from moisture.
Penicillin V Potassium for Oral Solution, USP, is available as a powder which when reconstituted as directed yields a red color, fruit-flavored solution.
NDC 67253-202-10 125 mg/5 mL-
100 mL individual bottles
NDC 67253-202-20 125 mg/5 mL-
200 mL individual bottles
When reconstituted according to the directions, each 5 mL contains Penicillin V Potassium equivalent to 125 mg (200,000 units) of Penicillin V.
NDC 67253-203-10 250 mg/5 mL-
100 ml individual bottles
NDC 67253-203-20 250 mg/5 mL-
200 mL individual bottles
When reconstituted according to the directions, each 5 mL contains Penicillin V Potassium equivalent to 250 mg (400,000 units) of Penicillin V.
Store the dry powder at 20° to 25°C (68 to 77°F). [See USP Controlled Room Temperature]. Protect from moisture. Keep bottle tightly closed. After reconstitution: Store in a refrigerator. Discard unused portion after 14 days.
Manufactured for:
DAVA Pharmaceuticals, Inc.
Fort Lee, NJ 07024, USA
by:
Suir Pharma Ireland Ltd.
Clonmel, Ireland.
Rev. 03/2014
Blenheim Pharmacal, Inc.
NDC 10544-297-20
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
500 mg
20 tablets Rx Only
500 mg equivalent to 800,000 units Penicillin V.
Blenheim Pharmacal, Inc.
NDC 10544-296-20
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
250 mg
20 tablets Rx Only
250 mg equivalent to 400,000 units Penicillin V.
Blenheim Pharmacal, Inc.
NDC 10544-296-28
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
250 mg
28 tablets Rx Only
250 mg equivalent to 400,000 units Penicillin V.
Blenheim Pharmacal, Inc.
NDC 10544-296-40
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
250 mg
40 tablets Rx Only
250 mg equivalent to 400,000 units Penicillin V.
Penicillin V is the phenoxymethyl analog of penicillin G. Penicillin V potassium is the potassium salt of penicillin V. Penicillin V Potassium is designated chemically as 4-Thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo- 6-[(phenoxyacetyl)amino]-, monopotassium salt, [2S-(2α,5α,6β)]-. It has the following chemical structure:
The molecular formula is C 16H 17KN 2O 5S, and the molecular weight is 388.48.
Each tablet contains Penicillin V Potassium equivalent to 250 mg or 500 mg (400,000 or 800,000 units) of penicillin V.
Each Penicillin V Potassium tablet, USP, 250 mg contains 0.73 mEq (28.2 mg) of Potassium and each Penicillin V potassium tablet, USP, 500 mg contains 1.46 mEq (56.4 mg) of Potassium.
Each tablet also contains the following inactive ingredients: lactose, NF; magnesium stearate, NF; microcrystalline cellulose, NF; polyethylene glycol, NF; povidone, USP; sodium laurel sulfate, NF.
Each 5 mL when reconstituted as directed contains Penicillin V Potassium equivalent to 125 mg or 250 mg (200,000 or 400,000 units) of Penicillin V.
Each 5 mL of reconstituted Penicillin V Potassium for Oral Solution, USP, 125 mg per 5 mL contains 0.42 mEq (16.4 mg) of Potassium. Each 5 mL of reconstituted Penicillin V Potassium for Oral Solution, USP, 250 mg per 5 mL contains 0.85 mEq (32.8 mg) of Potassium.
Each 5 mL of reconstituted suspension also contains the following inactive ingredients: aspartame, NF; citric acid, USP; FD&C Red No. 40; flavors; primary taste modifier; saccharin sodium, USP; silicon dioxide, NF; sodium citrate, USP; sodium propionate, NF; sucrose, NF.
Blenheim Pharmacal, Inc.
NDC 10544-297-28
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
500 mg
28 tablets Rx Only
500 mg equivalent to 800,000 units Penicillin V.
Blenheim Pharmacal, Inc.
NDC 10544-297-30
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
500 mg
30 tablets Rx Only
500 mg equivalent to 800,000 units Penicillin V.
Blenheim Pharmacal, Inc.
NDC 10544-297-40
PENICILLIN V
POTASSIUM
TABLETS, USP
Equivalent to
500 mg
40 tablets Rx Only
500 mg equivalent to 800,000 units Penicillin V.
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 834061 | penicillin V potassium 250 MG Oral Tablet | PSN | 4 |
| 834102 | penicillin V potassium 500 MG Oral Tablet | PSN | 4 |
| 834061 | penicillin V potassium 250 MG Oral Tablet | SCD | 4 |
| 834102 | penicillin V potassium 500 MG Oral Tablet | SCD | 4 |
| 834061 | Penicillin V K+ 250 MG Oral Tablet | SY | 4 |
| 834102 | Penicillin V K+ 500 MG Oral Tablet | SY | 4 |
| 834061 | Penicillin V Pot 250 MG Oral Tablet | SY | 4 |
| 834102 | Penicillin V Pot 500 MG Oral Tablet | SY | 4 |
| Class | Version | Type | Effective |
|---|---|---|---|
| PENICILLIN V Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 9c9e02f7-1420-b137-8de0-89820016e6ca | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10544-296-20 | Penicillin V Potassium | 20 in 1 BOTTLE | TABLET | 20 | 4 | |
| 10544-296-28 | Penicillin V Potassium | 28 in 1 BOTTLE | TABLET | 28 | 4 | |
| 10544-296-40 | Penicillin V Potassium | 40 in 1 BOTTLE | TABLET | 40 | 4 | |
| 10544-297-20 | Penicillin V Potassium | 20 in 1 BOTTLE | TABLET | 20 | 4 | |
| 10544-297-28 | Penicillin V Potassium | 28 in 1 BOTTLE | TABLET | 28 | 4 | |
| 10544-297-30 | Penicillin V Potassium | 30 in 1 BOTTLE | TABLET | 30 | 4 | |
| 10544-297-40 | Penicillin V Potassium | 40 in 1 BOTTLE | TABLET | 40 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 10544-296 | PENICILLIN V POTASSIUM TABLET [BLENHEIM PHARMACAL, INC.] | 4 | Legacy NDC, 3 package rows | 20150304_30b88469-9074-4d60-bd95-9f6a4078e3b4.zip |
| 10544-297 | PENICILLIN V POTASSIUM TABLET [BLENHEIM PHARMACAL, INC.] | 4 | Legacy NDC, 4 package rows | 20150304_30b88469-9074-4d60-bd95-9f6a4078e3b4.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| PENICILLIN V POTASSIUM | ACTIVE INGREDIENT | 146T0TU1JB | 4 | |
| PENICILLIN V | ACTIVE MOIETY | Z61I075U2W | 4 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 4 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 4 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 4 | |
| POLYETHYLENE GLYCOLS | INACTIVE INGREDIENT | 3WJQ0SDW1A | 4 | |
| POVIDONES | INACTIVE INGREDIENT | FZ989GH94E | 4 | |
| SODIUM LAURYL SULFATE | INACTIVE INGREDIENT | 368GB5141J | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10544-296 | 10544-296-28, 10544-296-40, 10544-296-20 |
| 10544-297 | 10544-297-20, 10544-297-28, 10544-297-30, 10544-297-40 |
| 67253-200 | |
| 67253-201 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | SOLUTION / ORAL | 3000 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | CREAM / TOPICAL | 214 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | POWDER, FOR SUSPENSION / ORAL | 64 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | POWDER / VAGINAL | 3 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | PASTE / DENTAL | 1.5 %w/w | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 17 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SUSPENSION / ORAL | 4441 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, COATED / ORAL | 123 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | GEL / VAGINAL | 0.2 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | SHAMPOO, SUSPENSION / TOPICAL | 40 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | CREAM / VAGINAL | 12 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | SUSPENSION / ORAL | 705 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | PASTE, DENTIFRICE / DENTAL | 1.4 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | INSERT / VAGINAL | 15 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IMPLANT / INTRAVITREAL | 1.66 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 3 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE / ORAL | 2169 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE / ORAL | 1725 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | SUSPENSION, EXTENDED RELEASE / ORAL | 0.08 mg/1ml | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, EXTENDED RELEASE / ORAL | 5119 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | 368GB5141J | OINTMENT / TOPICAL | 14 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| POVIDONES | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A062935-001 | PENICILLIN V POTASSIUM | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 |
| Application-product | TE code |
|---|---|
| A062935-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062935-001 | PENICILLIN V POTASSIUM | EQ 500MG BASE | TABLET / ORAL | AB | 1988-11-23 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A062935-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A062935-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062935-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062935-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062935-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A062935-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062935-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062935-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062935-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062935-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062935-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062935-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A062935-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062935-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062935-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062935-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A062935-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062935-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A062935-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A062935-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A062935-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A062935-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A062935-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062935-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A062935-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A062935-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A062935-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A062935-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A062935-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A062935-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062935-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A062935-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A062935-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062935-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062935-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062935-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062935-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A062935-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A062935-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062935-001 | AB | 1 | 3a93d1ddd44b… |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A062936-001 | PENICILLIN V POTASSIUM | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 |
| Application-product | TE code |
|---|---|
| A062936-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062936-001 | PENICILLIN V POTASSIUM | EQ 250MG BASE | TABLET / ORAL | AB | 1988-11-25 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A062936-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A062936-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062936-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062936-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062936-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A062936-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062936-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062936-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062936-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062936-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062936-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062936-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A062936-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062936-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062936-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062936-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A062936-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062936-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A062936-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A062936-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A062936-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A062936-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A062936-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062936-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A062936-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A062936-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A062936-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A062936-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A062936-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A062936-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062936-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A062936-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A062936-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062936-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062936-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062936-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062936-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A062936-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A062936-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062936-001 | AB | 1 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 10694145-3d30-1fbf-e054-00144ff8d46c | 30b88469-9074-4d60-bd95-9f6a4078e3b4 | 2015-03-03 | Warnings, Adverse reactions | 10694145-3d30-1fbf-e054-00144ff8d46c 30b88469-9074-4d60-bd95-9f6a4078e3b4 |
Adverse event summaries are temporarily unavailable. Other product information remains available.